Citi analyst Joanne Wuensch is opening a “90-day positive Catalyst Watch” ahead of Boston Scientific announcing results of its ADVENT IDE trial in the second half. The firm notes that management has not committed to a specific date, but believes the data will likely be presented at either the ESC meeting at the end of August, the TCT meeting at the end of October or the AHA meeting in November. Citi keeps a Buy rating on Boston Scientific with a $63 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BSX:
- Boston Scientific price target raised to $58 from $52 at Stifel
- Boston Scientific price target raised to $56 from $53 at RBC Capital
- Boston Scientific price target raised to $55 from $45 at Deutsche Bank
- Boston Scientific commentary lowers odds of ShockWave deal, says Evercore
- Boston Scientific price target raised to $58 from $53 at Canaccord